ThermoGenesis Corp. May 2012

ThermoGenesis Corp.

May 2012

Safe Harbor

Certain matters discussed in this presentation are "forward-looking statements." These forward-looking statements can generally be identified as by the context of the statement that includes words such as the Company "expects," "anticipates" or words of similar import. Similarly, statements that describe the Company's future plans, initiatives, milestones, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of the Company and market valuations of its stock, which could cause actual results to differ materially from those currently anticipated, and other risks outlined from time-to-time in our reports filed with the Securities and Exchange Commission. Although the Company believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, the Company can give no assurance that its expectations will be attained, or that risk factors listed will not affect those results or expectations in the future. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Forward-looking statements made in this presentation are only made as of the date of this presentation and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

-ThermoGenesis Overview

We design and commercialize devices and disposable tools for the processing, storage and

administration of cell therapies

– A worldwide leader in cell processing and cryopreservation technology with a strong installed base currently generating $18M in annual revenue

Our Products:

(AXP) Automated, closed system for the separation of stem cells from cord blood

Automated cord blood cryopreservation system

(MXP ) Lab-based, closed system for the separation of stem cells from bone marrow

Point-of-Care, closed system for the separation of stem cells from bone marrow and production of PRP from whole blood

Disposable cord blood processing bag set

Our Partners

3

Key Highlights

• Strong installed base currently generating $18M in annual recurring revenue

– Cord Blood Registry (largest family bank); New York Cord Blood Bank (largest public bank) – 35+ cord blood banks (globally) process stem cells using our AXP System

– 100+ cord blood banks store stem cells in our BioArchive® _{System (more than 200 placed worldwide)}

• Recent selection of BioArchive by Canadian Blood Services for new public cord blood bank

– 4,000+ bone marrow procedures performed annually using our technologies

• Management realignment to focus on core capabilities

– Reduced annual operating expenses by 15%, or $2M (January 2012)

– Divest wound care business – expected to generate $2M in cash, to be completed 2012 • Continued reduction of operating expenses related to non-core businesses

– Outsource manufacturing – Lower cost, high quality

• Strategic realignment to parlay expertise into therapeutic delivery

– Partner to embed TG technologies into FDA approved biotherapeutics at point-of-care and in Cell Factory applications

– Pursue FDA approved biotherapeutics in Cardiac; CLI and Orthopedics – Expand direct service and sales capabilities

-Business Model – three dimensional growth

-New products

N

e

w

G

e

o

g

ra

p

h

ie

s

• Well positioned for organic and strategic growth

– Geographic Growth - Establishing foothold in Asia:

• Recent approval of AXP in India, BioArchive in China & Taiwan • China & Southeast Asia cord blood banking automation business to

commence following regulatory approval (expected 2012)

– New Products:

•

Arthrex for Res-Q 60 PRP &

BMC

•

Collection disposables

•

Adipose & Cord tissue

– Clinical Data:

•

Favorable data from two

Res-Q clinical evaluations

(CLI/long bone fracture)

– Strategic Alliances:

•

Near-term therapeutic/POC

strategic alliances targeting

cardiac and orthopedics

2-D

Growth

Potential

6

-2012 2013 2014 2015 2016 2017 2018 2019

TG’s Addressable Market by Phase

2020 2021 2022 2023 $50M $100M $500M $B’s

Tools Provider

Tools with On-Label

Indications (510k’s)

Tools embedded in

approved therapeutics

(TG owns BLA)

_{approved therapeutics}

Tools embedded in

(Partner owns BLA)

• Highest cell yield

• Turnkey scalable

• Closed Systems

• Faster

7

-Cord Blood Stem Cell Opportunity

Our Solution for Scaling – Automated Manufacturing Process

Market Metrics:

• Market size: $20M

• Current revenues: $6-7M/year* Attributes:

• Eliminates transient warming events

- Computer controlled freezing curve - Robotic and optical storage and retrieval

• Large sample capacity 3,600+ Milestones:

• Exploring market adjacencies

BioArchive

Market Metrics:

• Market size: $30M

• Current revenues: $6-7M/year Attributes:

• Highly scalable - 6 units in 30 mins

• High TNC & MNC cell recovery Milestones:

• Market share gains

• China registration

• Leverage installed base

AutoXpress

* Incl. $3M in manual disps

Cord Blood Processing Market in 2015 ($33M)1

52% of Market

Near-Term Cord Blood Growth Catalysts

• Achieve registration approvals in China for AXP/BioArchive/Res-Q; initiate commercial sales

• Aggressively grow share in cord blood: – Convert manual processing banks to

automated systems

– Lead China and India conversion from manual to automated

– Replace competitive automated systems – Be positioned for U.S. and European

market rebounds when economy recovers

8

-Cord Blood Processing Market Today ($30M)1 34% of Market 1 _{ThermoGenesis Estimate} KOOL 52% Other Auto 27% Other Manual 21% KOOL 34% Other Auto 30% Other Manual 36%

Bone Marrow Stem Cell & PRP Opportunity

Our Solution to the Challenges of Manual Processing

9

-• Highest cell yield

• Turnkey scalable

• Closed Systems

• Faster

Market Metrics: Today 2016

• Market size: <$10M $1.6B*

• Current revenues: $.5M/year Attributes:

• Highly scalable - 6 units in 30 mins

• High TNC & MNC cell recovery Milestones:

• Market share gains

• Cell factory applications (strategic Alliances) * Robin R Young NY Stem Cell Summit 2012

MarrowXpress®

Market Metrics: Today 2016

• Market size: $200M $1.6B*

• Current revenues: $1-2M/year Attributes:

• Point-of-care product

• High MNC cell recovery

• Flexible volume capacity Milestones:

• Q3 Arthrex ramp up (BMC/PRP)

• Market share gains

• China registration

Near & Mid-Term BMC Growth Opportunity

10

-• TG’s % of addressable market is ~15% today • We expect to double our % market share by 2015

• Leverage base platforms in bone marrow and PRP into new

indications/new markets, including spine, cartilage and cardiovascular • Develop new platform applications,

such as cord tissue and adipose tissue as new, less invasive cell sources are adopted

• Explore applications in cell collection, expansion and delivery

TG’s addressable market for top 5 indications

$100 $200 $300 $400 $500 $600 $700 $800 2012 2013 2014 2015 2016 2017 2018 S t e m C e ll R e v e n u e i n $ M Cardiac CLI Cartilage Repair Spinal procedures Cord Blood

Business Development Opportunity Matrix

Complement organic growth efforts with business development for new and

adjacent market opportunities

Cell Source Other Tissue Adipose Peripheral Blood Bone Marrow Cord Blood ThermoGenesis Today

Regenerative Medicine Delivery Continuum

Business Development Targets

11

Milestones

• New BD initiatives launched (2012)

• $2M Wound Care business divestiture (2012)

–

Continued base business organizational optimization

• Ramp up of China & SE Asia cord blood business (2012)

• Ramp up of Arthrex BMC and PRP business (2012)

-Management Team

• Matthew Plavan, CEO/CFO, Board Member

– Prior experience includes McKesson/Ernst & Young

• Hal Baker, VP, Commercial Operations & Marketing

– Prior experience includes Pall/Gambro Healthcare

• Ken Pappa, VP, Quality, Engineering & Operations

– Joined company in 2006 and has held several management positions, most recently VP, Operations & Engineering

– Prior experience with Hewlett-Packard/Agilent Technologies

• Kevin Cooksy, VP, Corporate Development, Scientific Affairs & Regulatory

– Prior experience includes Agilent Technologies/Nektar Therapeutics

-Key Highlights

• Strong installed base currently generating $18M in annual recurring revenue

– Cord Blood Registry (largest family bank); New York Cord Blood Bank (largest public bank) – 35+ cord blood banks (globally) process stem cells using our AXP System

– 100+ cord blood banks store stem cells in our BioArchive® _{System (more than 200 placed worldwide)}

• Recent selection of BioArchive by Canadian Blood Services for new public cord blood bank

– 4,000+ bone marrow procedures performed annually using our technologies

• Management realignment to focus on core capabilities

– Reduced annual operating expenses by 15%, or $2M (January 2012)

– Divest wound care business – expected to generate $2M in cash, to be completed 2012 • Continued reduction of operating expenses related to non-core businesses

– Outsource manufacturing – Lower cost, high quality

• Strategic realignment to parlay expertise into therapeutic delivery

– Partner to embed TG technologies into FDA approved biotherapeutics at point-of-care and in Cell Factory applications

– Pursue FDA approved biotherapeutics in Cardiac; CLI and Orthopedics – Expand direct service and sales capabilities

-Thank You